1st Quarter - Report · 2026

Filing UUID: 5b5f1f49-a9db-4818-bf7d-3b442043d3ce
Type: Q1 — 1st Quarter - Report
Period: first_quarter
Year: 2026
Posted: 2026-04-17 12:57:23
Income (reported): $60,000
Expenses (reported): —
Filing document: Open on lda.senate.gov

Registrant (lobbying firm)

MARSHALL & POPP, LLC

â€‹Government affairs and consulting firm.

Contact: BETH ANNE COLE
Phone: +1 202-321-1811
Address: zip:20003, city:Washington, state:DC, street:880 New Jersey Avenue, SE Unit 927

Client

ELI LILLY AND COMPANY

Biopharmaceutical manufacturer.

State: IN
Country: US
Effective date: 2025-03-14

Issues lobbied + lobbyists

`MMM` — Medicare/Medicaid

Issues related to treatments for Alzheimers therapeutics.

Lobbyists: HAZEN CLAY MARSHALL (covered position: Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles); MONICA POPP (covered position: Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint)

Government entities lobbied: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

`PHA` — Pharmacy

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals. Issues related to the 340B program.

Lobbyists: HAZEN CLAY MARSHALL; MONICA POPP